Lymphoma News Today

Skip to content
  • Home
  • News Categories
    • Social Clips
    • Hodgkin’s Lymphoma
    • Non-Hodgkin’s Lymphoma
    • Clinical Trial
    • Leukemia & Lymphoma Society
  • About Lymphoma
    • Types Of Lymphoma
      • B-Cell Lymphoma
      • Benign Lymphoma
      • Burkitt’s Lymphoma
      • Cutaneous Lymphoma
      • Follicular Lymphoma
      • Indolent Lymphoma
      • Intestinal Lymphoma
      • Low Grade Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
    • Lymphoma Symptoms
      • Lymphedema
    • Signs Of Lymphoma
    • Lymphoma Diagnosis
    • Lymphoma Prognosis
  • Treatments
    • Approved Treatments
      • CAR T-cell Therapy
        • Kymriah (Tisagenlecleucel)
        • Yescarta (KTE-C19)
      • Adcetris (Brentuximab Vedotin)
      • Aliqopa (Copanlisib)
      • Arzerra (Ofatumumab)
      • Beleodaq (Belinostat)
      • Bendamustine in Lymphomas
      • Besponsa (Inotuzumab Ozogamicin)
      • Calquence (Acalabrutinib)
      • CPX-351
      • Gazyva (Obinutuzumab)
      • Imbruvica (Ibrutinib)
      • Keytruda for Classical Hodgkin Lymphoma (cHL)
      • Rituxan (Rituximab)
      • Rituxan Hycela
      • Revlimid (lenalidomide)
      • Velcade (bortezomib)
      • Venclexta (Venetoclax)
      • Zydelig (Idelalisib)
    • Experimental Treatments
      • ABP798 for Non-Hodgkin’s Lymphoma
      • ADCT-301 in Lymphomas
      • AFM11 for B-Cell Lymphoma
      • AFM13 for Hodgkin’s Lymphoma
      • ALT-803 for Non-Hodgkin Lymphomas
      • Betalutin
      • CMD-003 for Hodgkin’s and non-Hodgkin’s Lymphomas
      • CX-072
      • CPI-818
      • DI-Leu16-IL2
      • Duvelisib
      • GWN323
      • IGN002 for Non-Hodgkin’s Lymphoma
      • Imfinzi (Durvalumab)
      • JCAR017 for B-Cell Non-Hodgkin’s Lymphoma (NHL)
      • JCAR018
      • KTE-X19
      • Mogamulizumab
      • NM-IL-12
      • Oncoquest-L for Follicular Lymphoma
      • OXS-1550
      • PDR001 in Lymphoma
      • Resimmune
      • RG7741 (GDC-0575)
      • Tecentriq (Atezolizumab)
      • TG-1101 (Ublituximab)
      • TGR-1202 (Umbralisib)
      • Xalkori (Crizotinib)
  • Columns
    • Overcoming Adversity
    • Things That Give Me Hope
    • Life After Lymphoma: A Young Warrior’s Guide to Recovery
  • Information About COVID-19

Gazyva Plus CHOP Brings No New Benefits to Diffuse Large B-Cell Lymphoma Patients in Phase 3 Study

July 19, 2016July 19, 2016
Ines Martins, PhDby Ines Martins, PhD

In News.

Gazyva Plus CHOP Brings No New Benefits to Diffuse Large B-Cell Lymphoma Patients in Phase 3 Study

Click here to subscribe to the Lymphoma News Today Newsletter!

0
(0)

Patients with previously untreated diffuse large B-cell lymphoma (DLBCL)  given Gazyva/Gazyvaro (obinutuzumab) plus standard chemotherapy (CHOP) do not have higher progression-free survival rates than those treated with Rituxan/MabThera (rituximab), according to new data from the Phase 3 GOYA study. The trial’s results will soon be presented at a medical meeting.

“Two previous studies showed Gazyva/Gazyvaro helped people with previously untreated follicular lymphoma or chronic lymphocytic leukaemia live longer without their disease worsening compared to MabThera/Rituxan, when each was combined with chemotherapy,” Sandra Horning, MD, chief medical officer and head of Global Product Development at Roche, said in a press release. “We were hopeful we could show a similar result for people with diffuse large B-cell lymphoma and once again improve on the standard of care.”

Obinutuzumab is a monoclonal antibody that targets the CD20 protein, expressed at the surface of certain B-cells, but not stem cells or plasma cells.

The combination of obinutuzumab plus chlorambucil is currently approved in more than 70 countries after results from the CLL11 Phase 3 study, where this combination was found to significantly improve progression-free survival (PFS), overall response rate, complete response rate, and minimal residual disease in patients with chronic lymphocytic leukemia, compared to rituximab plus chlorambucil.

Early this year, the U.S. Food and Drug Administration (FDA) also approved obinutuzumab, known as Gazyva in the U.S., in combination with bendamustine followed by obinutuzumab maintenance for follicular lymphoma patients who did not respond to a therapy regimen containing rituximab. Similarly, obinutuzumab received a similar approval by the European Commission, where it is known as Gazyvaro, in June 2016.

Researchers developed the randomized, open-label, multicenter GOYA study to examine the efficacy of obinutuzumab plus CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone) chemotherapy (a treatment called G-CHOP), compared to rituximab plus CHOP (R-CHOP), in patients with untreated DLBCL.

The study enrolled 1,418 patients with CD20-positive untreated DLBCL and its primary endpoint was investigator-assessed PFS. Secondary endpoints included independent review committee-assessed PFS, overall response rate, complete response rate, overall survival, disease free survival, and safety profile.

Preliminary results announced by Roche reveal that the study did not meet its primary endpoint of improved PFS in patients treated with G-CHOP versus R-CHOP. Adverse events in both arms were similar to those obtained in previous studies were obinutuzumab and rituximab were combined with other chemotherapies, the data shows.

“We will continue to analyse the GOYA data to better understand the results, and to study other investigational treatments in this disease with the goal of further helping these patients,” Horning concluded.

Print Friendly, PDF & EmailPrint This Page

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Tagged B-cell-like diffuse large B-cell lymphomas, CHOP, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, Gazyva, Gazyvaro, GOYA, Obinutuzumab, R-CHOP, rituximab.

Post navigation

Specific enzyme that participates in cancer progressionPrevious: Blood Cancer Patients Who Relapsed After Stem-Cell Transplant May Benefit from Immunotherapy
clinical trial resultsNext:Five-Year Trial Results Show Efficacy of Adcetris in Treating Hodgkin’s Lymphoma

Recent Posts

  • farewell, honesty, impact, sometimes, superheroes

    A Farewell Note to My Beloved Readers

    February 26, 2021

  • farewell, honesty, impact, sometimes, superheroes

    A Light-giver Shares a Lesson in Emotional Honesty

    February 15, 2021

  • farewell, honesty, impact, sometimes, superheroes

    Embarking on a New Chapter While Cherishing the Value of Community

    February 1, 2021

Featured Posts

FDA Grants Orphan Drug Status to Umbralisib for Follicular Lymphoma

March 19, 2020

Umbralisib orphan drug

The Paradox of Healing

March 9, 2020

grateful, happiness, coronavirus, beauty
Visit Lymphoma News Today's profile on Pinterest.

Lymphoma News Today

BioNews Services, LLC
3 W Garden St
Suite 700
Pensacola, FL 32502
Email: [email protected]
Phone: +1-800-936-1363
  • About Us
  • Our Team
  • Our Guiding Ethics
  • Contact Us
  • Terms of Service
  • Privacy Policy
  • Disable Notifications

Disclaimer:

Lymphoma News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Copyright © 2013-2023 Copyright 2015 © All rights reserved